tirzepatide 2022 Day 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for New Blockbuster Type 2 Medication

It should clearly say "U-100" or show 100 units per mL

It typically begins around week 3 or 4 as doses increase, peaks during weeks 6 through 8, and substantially improves by week 12

NCT07184086 | A Study to See How Metabolism is

Non-invasive tests (NITs) in ESSENCE showed changes concordant with histologic improvements

Immunoprophylactic potential of filarial glutathione-s-transferase in lymphatic [PMID: 21771450] Laboratory literature summary: Immunoprophylactic potential of filarial glutathione-s-transferase in lymphatic filariaisis

For weight management without diabetes, the role of metformin is less established and stopping it may be appropriate if tirzepatide alone is achieving your goals